In a regulatory filing, Maravai Lifesciences (MRVI) disclosed that its director Gregory Lucier bought 100K shares of common stock on December 5th as part of option exercise. Shares are up 9% afterhours at $4.01.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Closing Bell Movers: Inotiv surges after quarterly results
- Maravai Lifesciences CEO buys $702.7K of class A shares
- Maravai LifeSciences Earnings Call: Mixed Signals
- Maravai Lifesciences price target lowered to $4 from $5 at Stifel
- Cautious Optimism for Maravai Lifesciences: Hold Rating Amidst Strategic Recovery Efforts